Table 1.
Immunophenotype of PL-MSCs, BM-MSCs, and WJ-MSCs.
| Marker | PL-MSCs (% ±SD) | BM-MSCs (% ±SD) | WJ-MSCs (% ±SD) |
|---|---|---|---|
| CD105 | 96 ± 3 | 90 ± 13 | 99.8 ± 0.1 |
| CD90 | 72.7 ± 27 | 85 ± 15 | 100 |
| CD73 | 88 ± 9 | 97 ± 3 | 95.5 ± 6.6 |
| CD13 | 98 ± 3 | 98 ± 1 | 97.8 ± 2.7 |
| HLA-ABC | 68 ± 30 | 94 ± 9 | 56.6 ± 32.1 |
| CD45 | 2 ± 3 | 1 ± 1 | 0.1 ± 0.1 |
| CD34 | 0 | 0 | 0.9 ± 0.8 |
| CD31 | 1 ± 1 | 1 ± 1 | 6.6 ± 6.3 |
| CD14 | 1 ± 1 | 2 ± 2 | 0.4 ± 0.3 |
| HLA-DR | 1 ± 1 | 3 ± 3 | 3.6 ± 4.9 |
PL-MSCs: placenta mesenchymal stem cells; BM-MSCs: bone marrow mesenchymal stem cells; WJ-MSCs: Wharton’s jelly mesenchymal stem cells; SD: standard deviation.
The results are expressed as percentage of positive cells. SD of three experiments, with at least >10,000 events per sample, was counted (n = 3).